JPH0455405B2 - - Google Patents
Info
- Publication number
- JPH0455405B2 JPH0455405B2 JP3802486A JP3802486A JPH0455405B2 JP H0455405 B2 JPH0455405 B2 JP H0455405B2 JP 3802486 A JP3802486 A JP 3802486A JP 3802486 A JP3802486 A JP 3802486A JP H0455405 B2 JPH0455405 B2 JP H0455405B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- administered
- compounds
- pyrrolidone
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002664 nootropic agent Substances 0.000 claims description 4
- WGOIHPRRFBCVBZ-VKHMYHEASA-N (2s)-5-oxopyrrolidine-2-carboxamide Chemical group NC(=O)[C@@H]1CCC(=O)N1 WGOIHPRRFBCVBZ-VKHMYHEASA-N 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- -1 pyrrolidino, piperidino Chemical group 0.000 claims description 2
- WGOIHPRRFBCVBZ-GSVOUGTGSA-N (2r)-5-oxopyrrolidine-2-carboxamide Chemical group NC(=O)[C@H]1CCC(=O)N1 WGOIHPRRFBCVBZ-GSVOUGTGSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 208000000044 Amnesia Diseases 0.000 description 7
- 208000031091 Amnestic disease Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000006986 amnesia Effects 0.000 description 7
- GOWRRBABHQUJMX-UHFFFAOYSA-N fasoracetam Chemical compound C1CCCCN1C(=O)C1CCC(=O)N1 GOWRRBABHQUJMX-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000001777 nootropic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LLZWOOMWJQIHAW-ZETCQYMHSA-N (2S)-1-morpholin-4-yl-5-oxopyrrolidine-2-carboxamide Chemical compound O1CCN(CC1)N1[C@@H](CCC1=O)C(=O)N LLZWOOMWJQIHAW-ZETCQYMHSA-N 0.000 description 1
- JEOVABNPJMHXGZ-QMMMGPOBSA-N (2S)-5-oxo-1-piperidin-1-ylpyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CCC(=O)N1N1CCCCC1 JEOVABNPJMHXGZ-QMMMGPOBSA-N 0.000 description 1
- YQXLOVXVWICTBX-ZETCQYMHSA-N (2S)-5-oxo-1-pyrrolidin-1-ylpyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CCC(=O)N1N1CCCC1 YQXLOVXVWICTBX-ZETCQYMHSA-N 0.000 description 1
- WPDJMBAXQKFEOI-UHFFFAOYSA-N 5-(morpholine-4-carbonyl)pyrrolidin-2-one Chemical compound C1COCCN1C(=O)C1CCC(=O)N1 WPDJMBAXQKFEOI-UHFFFAOYSA-N 0.000 description 1
- IWMYEQSITOXBMZ-UHFFFAOYSA-N 5-(pyrrolidine-1-carbonyl)pyrrolidin-2-one Chemical compound C1CCCN1C(=O)C1CCC(=O)N1 IWMYEQSITOXBMZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100032251 Pro-thyrotropin-releasing hormone Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1136086 | 1986-01-21 | ||
| JP61-11360 | 1986-01-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62252761A JPS62252761A (ja) | 1987-11-04 |
| JPH0455405B2 true JPH0455405B2 (cs) | 1992-09-03 |
Family
ID=11775857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3802486A Granted JPS62252761A (ja) | 1986-01-21 | 1986-02-21 | 向知性剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62252761A (cs) |
-
1986
- 1986-02-21 JP JP3802486A patent/JPS62252761A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62252761A (ja) | 1987-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU593051B2 (en) | Method of treating alzheimer's disease | |
| US6191153B1 (en) | Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity | |
| JP2001513496A (ja) | 注意欠陥障害を治療するためのコリンエステラーゼ阻害剤の使用 | |
| US4372960A (en) | Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators | |
| EP1020189B1 (en) | Nefiracetam for prevention and treatment of amnesia caused by propofol | |
| JPS5910585A (ja) | スピロスクシンイミド誘導体のアルツハイマ−型痴「ほう」の治療における使用 | |
| CA2362918A1 (en) | Methods and compositions for treating erectile dysfunction | |
| EP0546547B1 (en) | Pharmaceutical composition for the improvement of dysuria | |
| JPH0455405B2 (cs) | ||
| US4404226A (en) | Use of guanfacine in treating schizophrenia | |
| US20010051653A1 (en) | Method for improving disturbancies of activities of daily living after stroke | |
| KR0177894B1 (ko) | 항우울제 | |
| US3720768A (en) | Aspergillic acid as an antihypertensive agent | |
| US3354036A (en) | Method of producing depression | |
| DE3816937C2 (cs) | ||
| JPH11503721A (ja) | ベンズアミド誘導体の新規用途 | |
| JPS6116A (ja) | 有機化合物に関する改良 | |
| US3743746A (en) | Process of treating peptic ulcer with a non-anticholinergic agent | |
| JPS63287725A (ja) | 向知性薬 | |
| MXPA04012706A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
| US3895114A (en) | Cyclic hydroxamic acids as antihypertensive agents | |
| US4297356A (en) | Memory enhancer containing 2-(7-indenyloxymethyl-morpholine | |
| JPH0692304B2 (ja) | 向知性薬 | |
| JPH0374330A (ja) | 脱髄疾患治療剤 | |
| JPWO2002045715A1 (ja) | 抗痴呆効果増強剤 |